These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease. Gu J; Sanchez RJ; Chauhan A; Fazio S; Rosenson RS J Clin Lipidol; 2022; 16(6):901-905. PubMed ID: 36319536 [TBL] [Abstract][Full Text] [Related]
12. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Miname MH; Santos RD Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498 [TBL] [Abstract][Full Text] [Related]
13. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Wójcik C Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791 [TBL] [Abstract][Full Text] [Related]
14. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086 [TBL] [Abstract][Full Text] [Related]
15. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300 [TBL] [Abstract][Full Text] [Related]
16. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. Hess CN; Low Wang CC; Hiatt WR Annu Rev Med; 2018 Jan; 69():133-145. PubMed ID: 29095667 [TBL] [Abstract][Full Text] [Related]
17. Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta. Chen G; Farris MS; Cowling T; Colgan SM; Xiang P; Pericleous L; Rogoza RM; Tai MH; Anderson T Can J Cardiol; 2019 Jul; 35(7):884-891. PubMed ID: 31292087 [TBL] [Abstract][Full Text] [Related]
18. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517 [TBL] [Abstract][Full Text] [Related]
19. Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk. Katzmann JL; Becker C; Bilitou A; Laufs U PLoS One; 2022; 17(10):e0276898. PubMed ID: 36301892 [TBL] [Abstract][Full Text] [Related]
20. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]